NLRP3 and ischemic stroke: JLX001, a novel compound structurally similar to cycloviral flavonoid D (CVB-D), inhibits the expression of NLRP3 and proteins associated with the NLRP3 inflammasome axis in vivo, promoting a transition to a microglial M2 phenotype, suggesting that JLX001 is a promising treatment for ischemic stroke (114).